news.google.com· FierceBiotech·· 1 day agoPickScore54
Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal - Fierce Biotech
In brief
Menarini's Stemline has struck a $1.1B deal to license a preclinical cancer immunotherapy from Georgiamune. The program is currently at the preclinical stage.
Why it matters
Deal value and preclinical stage are clear, allowing assessment of the scale of Stemline's investment in the Georgiamune immunotherapy program.
Source: news.google.com · news.google.com